Study Stopped
Study was closed to accrual on January 15, 2020.
Establishment of a PDT Patient Registry
Establishment of a Registry for Patients Treated With Photodynamic Therapy (PDT)
1 other identifier
observational
22
1 country
10
Brief Summary
This is a non-intervention patient registry to gather data on the use of photodynamic therapy under real-life conditions. It will involve up to 20 sites in USA.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Jan 2019
Shorter than P25 for all trials
10 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 5, 2018
CompletedFirst Posted
Study publicly available on registry
July 17, 2018
CompletedStudy Start
First participant enrolled
January 18, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 15, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
January 15, 2020
CompletedFebruary 24, 2020
February 1, 2020
12 months
July 5, 2018
February 20, 2020
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
PDT Outcome
Collection of information on patient characteristics, disease sites, and utilization of prior or combined treatments to evaluate the impact of these parameters on the treatment outcome
Up to 5-year follow-up
Interventions
There are no interventions associated with this registry as it is purely observational.
Eligibility Criteria
It is intended to enroll all types of subjects requiring PDT for cancer.
You may qualify if:
- All adult patients (≥ 18 years of age) treated with PDT.
- Women and men and members of all races and ethnic groups.
- Subjects may have received prior treatment for their cancer.
- Subjects to give a written informed consent for prospectively collected data.
You may not qualify if:
- None.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Concordia Laboratories Inc.lead
- Roswell Park Cancer Institutecollaborator
Study Sites (10)
John Muir Clinical Research Center
Concord, California, 94520, United States
Cedars-Sinai Medical Center
Los Angeles, California, 90048, United States
University of Florida
Gainesville, Florida, 32610, United States
University of Chicago
Chicago, Illinois, 60637, United States
Alexian Brothers Hospital Network
Lisle, Illinois, 60532, United States
Duke University Medical Center
Durham, North Carolina, 27710, United States
Clinical Research Associates of Central PA
Altoona, Pennsylvania, 16602, United States
Medical University of South Carolina
Charleston, South Carolina, 29425, United States
Providence Sacred Heart Medical Center
Spokane, Washington, 99204, United States
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Sandra Gollnick, Ph.D.
Roswell Park Cancer Institute
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- OTHER
- Target Duration
- 5 Years
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 5, 2018
First Posted
July 17, 2018
Study Start
January 18, 2019
Primary Completion
January 15, 2020
Study Completion
January 15, 2020
Last Updated
February 24, 2020
Record last verified: 2020-02